Male fertility after VAPEC-B chemotherapy for Hodgkin's disease and non-Hodgkin's lymphoma.

2.50
Hdl Handle:
http://hdl.handle.net/10541/97142
Title:
Male fertility after VAPEC-B chemotherapy for Hodgkin's disease and non-Hodgkin's lymphoma.
Authors:
Radford, John A ( 0000-0001-7898-2786 ) ; Clark, S; Crowther, Derek; Shalet, Stephen M
Abstract:
Semen analysis was performed in 14 men a median of 13.5 months after completion of VAPEC-B chemotherapy for Hodgkin's disease or non-Hodgkin's lymphoma. Semen from 12 patients contained motile spermatozoa, and in nine cases the count was > 20 million ml-1. One patient was azoospermic (VAPEC-B followed by pelvic radiotherapy) and another had a count of 21 million ml-1 but sperm were non-motile. These findings suggest that, in the majority of cases, VAPEC-B chemotherapy does not cause permanent damage to the male germinal epithelium. A more detailed study of gonadal function in males and females before and after treatment with VAPEC-B for Hodgkin's disease is currently in progress.
Affiliation:
CRC Department of Medical Oncology, Christie Hospital, Manchester, UK.
Citation:
Male fertility after VAPEC-B chemotherapy for Hodgkin's disease and non-Hodgkin's lymphoma. 1994, 69 (2):379-81 Br. J. Cancer
Journal:
British Journal of Cancer
Issue Date:
Feb-1994
URI:
http://hdl.handle.net/10541/97142
PubMed ID:
7507693
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorRadford, John Aen
dc.contributor.authorClark, Sen
dc.contributor.authorCrowther, Dereken
dc.contributor.authorShalet, Stephen Men
dc.date.accessioned2010-04-22T10:42:21Z-
dc.date.available2010-04-22T10:42:21Z-
dc.date.issued1994-02-
dc.identifier.citationMale fertility after VAPEC-B chemotherapy for Hodgkin's disease and non-Hodgkin's lymphoma. 1994, 69 (2):379-81 Br. J. Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid7507693-
dc.identifier.urihttp://hdl.handle.net/10541/97142-
dc.description.abstractSemen analysis was performed in 14 men a median of 13.5 months after completion of VAPEC-B chemotherapy for Hodgkin's disease or non-Hodgkin's lymphoma. Semen from 12 patients contained motile spermatozoa, and in nine cases the count was > 20 million ml-1. One patient was azoospermic (VAPEC-B followed by pelvic radiotherapy) and another had a count of 21 million ml-1 but sperm were non-motile. These findings suggest that, in the majority of cases, VAPEC-B chemotherapy does not cause permanent damage to the male germinal epithelium. A more detailed study of gonadal function in males and females before and after treatment with VAPEC-B for Hodgkin's disease is currently in progress.en
dc.language.isoenen
dc.subject.meshAdolescent-
dc.subject.meshAdult-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshBleomycin-
dc.subject.meshCyclophosphamide-
dc.subject.meshDoxorubicin-
dc.subject.meshEtoposide-
dc.subject.meshHodgkin Disease-
dc.subject.meshHumans-
dc.subject.meshLymphoma, Non-Hodgkin-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshSperm Count-
dc.subject.meshSperm Motility-
dc.subject.meshVincristine-
dc.titleMale fertility after VAPEC-B chemotherapy for Hodgkin's disease and non-Hodgkin's lymphoma.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Medical Oncology, Christie Hospital, Manchester, UK.en
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.